Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in *Brca1*-deficient mice

Di Zhang^{1*}, Bijay Singh^{2,3*}, Jessica Moerland¹, Owen Mitchell¹, Lizbeth Lockwood¹, Sarah Carapellucci¹, Srinivas Sridhar^{2,3}, Karen T. Liby¹


Authors' affiliations: ¹Michigan State University, East Lansing, MI; ²Theranano LLC, Newton, MA; ³Northeastern University, Boston, MA.

^{*} These authors contributed equally to this work.


Exposure of γ H2AX and Vinculin

Viantin


Longer exposure of γ H2AX




Shorter exposure of Vinculin



Exposure of c-caspase 3




Exposure of PARP and cleaved-PARP




Exposure of Cyclin D1









Suppl. Fig.1: Immunoblots used in Fig.2A.